Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Aura Biosciences, Inc. - Common Stock (NQ:AURA)

5.920 -0.130 (-2.15%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 6, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Aura Biosciences, Inc. - Common Stock

< Previous 1 2 Next >
3 Small-Cap Stocks Ready to Deliver Significant Growth
Small-cap firms will have an easier time borrowing money for growth in a lower-interest-rate environment; these are a few companies poised for a breakout. 
Via MarketBeat
Topics Economy
Aura Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights
From Aura Biosciences, Inc.
Via Business Wire
Aura Biosciences to Participate in Upcoming Investor Conferences
From Aura Biosciences Inc.
Via Business Wire
Aura Biosciences Announces First Patient Dosed in Global Phase 3 CoMpass Trial Evaluating the Safety and Efficacy of Belzupacap Sarotalocan (Bel-sar) for First-Line Treatment of Early-Stage Choroidal Melanoma
From Aura Biosciences Inc.
Via Business Wire
Aura Biosciences Reports Third Quarter 2023 Financial Results and Provides Clinical Development and Operational Highlights
From Aura Biosciences, Inc.
Via Business Wire
Aura Biosciences to Participate in Upcoming Investor Conferences
From Aura Biosciences Inc.
Via Business Wire
Aura Biosciences Announces Pricing of Public Offering of Common Stock
From Aura Biosciences, Inc.
Via Business Wire
Aura Biosciences Announces Proposed Public Offering of Common Stock
From Aura Biosciences, Inc.
Via Business Wire
Aura Biosciences Receives FDA Agreement Under Special Protocol Assessment (SPA) for CoMpass Phase 3 Clinical Trial of Belzupacap Sarotalocan (Bel-sar) in Early-stage Choroidal Melanoma
From Aura Biosciences, Inc.
Via Business Wire
Aura Biosciences to Present Updated Phase 2 Data Evaluating Suprachoroidal Administration of Belzupacap Sarotalocan (Bel-sar) for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma at AAO 2023
From Aura Biosciences Inc.
Via Business Wire
Aura Biosciences Strengthens and Expands Leadership Team with Key Appointments
From Aura Biosciences Inc.
Via Business Wire
Aura Biosciences Reports Second Quarter 2023 Financial Results and Provides Clinical Development and Operational Highlights
From Aura Biosciences Inc.
Via Business Wire
Aura Biosciences to Participate in Upcoming Investor Conferences
From Aura Biosciences Inc.
Via Business Wire
Aura Biosciences to Participate in the JMP Securities Life Sciences Conference
From Aura Biosciences Inc.
Via Business Wire
Aura Biosciences Reports First Quarter 2023 Financial Results and Provides Clinical Development and Operational Highlights
From Aura Biosciences Inc.
Via Business Wire
Aura Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Clinical Development and Operational Highlights
From Aura Biosciences Inc.
Via Business Wire
Aura Biosciences Announces Positive Interim Phase 2 Safety and Efficacy Data of Belzupacap Sarotalocan (Bel-sar) for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma with Suprachoroidal Administration
From Aura Biosciences, Inc.
Via Business Wire
Aura Biosciences to Participate in Upcoming Investor Conferences
From Aura Biosciences Inc.
Via Business Wire
Aura Biosciences Announces Pricing of Public Offering of Common Stock
From Aura Biosciences, Inc.
Via Business Wire
Aura Biosciences Announces Proposed Public Offering of Common Stock
From Aura Biosciences, Inc.
Via Business Wire
Aura Biosciences Reports Third Quarter 2022 Financial Results and Provides Clinical Development and Operational Highlights
From Aura Biosciences
Via Business Wire
Aura Announces Global Phase 3 Trial Design with Suprachoroidal Route of Administration Based on Positive Phase 2 Interim Data of Belzupacap Sarotalocan in Early-Stage Choroidal Melanoma
From Aura Biosciences, Inc.
Via Business Wire
Aura Biosciences to Participate in Upcoming Investor Conferences
From Aura Biosciences Inc.
Via Business Wire
Aura Biosciences Announces Interim Phase 2 Data Evaluating Suprachoroidal Administration of Belzupacap Sarotalocan (AU-011) for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma Presented at AAO 2022
From Aura Biosciences, Inc.
Via Business Wire
Aura Biosciences Announces First Patient Dosed in Phase 1 Study Evaluating Belzupacap Sarotalocan (AU-011) for the Treatment of Non-Muscle Invasive Bladder Cancer
From Aura Biosciences, Inc.
Via Business Wire
Aura Biosciences to Present Ongoing Phase 2 Data Evaluating Suprachoroidal Administration of Belzupacap Sarotalocan (AU-011) for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma at AAO 2022
From Aura Biosciences, Inc.
Via Business Wire
Aura Biosciences to Present Phase 2 Safety Data Evaluating Suprachoroidal Administration of Belzupacap Sarotalocan (AU-011) in Patients with Choroidal Melanoma at the ESMO 2022 Congress
From Aura Biosciences Inc.
Via Business Wire
Aura Biosciences to Present Belzupacap Sarotalocan (AU-011) Data from Multiple Studies at the 22nd EURETINA Congress
From Aura Biosciences Inc.
Via Business Wire
Aura Biosciences Reports Second Quarter 2022 Financial Results and Provides Clinical Development and Operational Highlights
From Aura Biosciences Inc.
Via Business Wire
Aura Biosciences to Participate at the 2022 BTIG Biotechnology Conference
From Aura Biosciences, Inc.
Via Business Wire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.